“…(2004a,b) describe the use of dexmedetomidine in primates, but the currently available commercial formulation offers no volume reduction compared to standard preparations of medetomidine (1 mg mL −1 ). Hess et al. (2010) describe the use of naphthylmedetomidine in a 10 mg mL −1 formulation, resulting in a low volume, with promising cardiovascular and behavioural effects of for non‐painful procedures in primates.…”